Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | HINT1 | P49773 | 2/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107681 | 0.95 | HPGD (0.37) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL15878701 | 0.94 | HPGD (0.36) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL3905624 | 0.89 | HPGD (0.37) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2108084 | 0.89 | HPGD (0.38) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2215262 | 0.85 | TYMP (0.43) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2213753 | 0.84 | CARM1 (0.34) | TYMP | |
| SCHEMBL15048538 | 0.84 | CARM1 (0.34) | TYMP | |
| SCHEMBL12513080 | 0.84 | TYMP (0.40) | TYMPTAS1R3TAS1R1 | |
| SCHEMBL2106148 | 0.84 | TYMP (0.42) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL15841440 | 0.83 | TYMP (0.41) | HPGDTAAR1TYMPTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470987-B2 | Protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | CHIRALGEN, LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178284-A1 | Novel protective group for synthesis of RNA and derivative | RNGTT, FBL, RNASEH1 | HPGD 1858/4885TAAR1 3177/4885TYMP 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.